USA flag logo/image

An Official Website of the United States Government

Establishing a comprehensive inhibitory profile of marketed drugs against CNS…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43FD004297
Solicitation Year:
2011
Solicitation Topic Code:
FDA
Solicitation Number:
PA10-050
Small Business Information
OPTIVIA BIOTECHNOLOGY, INC.
115 CONSTITUTION DR, STE 7 MENLO PARK, CA 94025-3712
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Establishing a comprehensive inhibitory profile of marketed drugs against CNS tra
Agency: HHS
Contract: 1R43FD004297-01
Award Amount: $150,000.00
 

Abstract:

DESCRIPTION (provided by applicant): CNS Transporters have crucial roles on neurophysiology and etiology. Inhibition of these critical transporters can have therapeutic benefits or cause serious side effects in the CNS. Development of an assay platform anda comprehensive profile of drugs' inhibitory effects on important CNS transporters can have enormous impact on drug discovery and development, such as elucidating drugs' potential side effects in the CNS, and advancing development of new drugs to treat various CNS diseases, such as Alzheimer's disease, Parkinson's diseases, epilepsy etc., The overall goal of this project is to develop a comprehensive assay platform for evaluating drugs' inhibitory effects on key CNS transporters, and then to establish theindustry's largest database on inhibitory effects of over 1000 prescription CNS and peripherally acting drugs on these transporters. The initial Phase I work will start with developing assays for 10 crucial CNS transporters, which are known as therapeutictargets or to play critical roles on CNS physiology. A small library of marketed CNS drugs will then be profiled for their inhibitory effects on these transporters, with aims to reveal possible interactions of the drugs with these transporters that are previously unknown to the research community. Future study would extend the scope to developing assays for more than 30 major CNS transporters, and scale up inhibitory profiling efforts for more than 1000 marketed drugs, with aims to explain causes of certainCNS side effects, to reveal potential new therapeutic indications of existing drugs, and to discover potential therapeutic benefits of inhibiting certain key CNS transporters in treating various CNS diseases. PUBLIC HEALTH RELEVANCE: Success of this project would benefit public health enormously through helping inform and mitigate drugs' potential side effects in the CNS, and by helping develop pharmaceuticals to treat various serious CNS disorders, such as Parkinson's disease, Alzheimer's disease,epilepsy etc.. Specifically, the proposed studies will be invaluable for evaluating off-target effects of both CNS and peripherally acting drugs on critical CNS transporters of physiological and/or pharmacological significance, which could potentially leadto discovering new therapeutic indications for marketed CNS drugs, and identifying/validating novel molecular targets for therapeutic intervention.

Principal Investigator:

Juan J. Fung
650-725-7754
jjfung@optiviabio.com

Business Contact:

Juan Fung
650-324-3177
yhuang@optiviabio.com
Small Business Information at Submission:

OPTIVIA BIOTECHNOLOGY, INC.
OPTIVIA BIOTECHNOLOGY, INC. 115 CONSTITUTION DR, STE 7 MENLO PARK, CA 94025-3712

EIN/Tax ID: 126014876
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No